Boston Scientific reported third-quarter revenue of $5.138 billion, representing 1.5% year-over-year growth, while adjusted earnings declined to $0.73 per share from $0.75.
The company reduced its full-year adjusted EPS guidance to $3.16–$3.18 and projected a fourth-quarter revenue decline of 1%–3%.
Management identified continued pressure from China's volume-based procurement program, weaker performance in electrophysiology and WATCHMAN-related businesses, and lingering effects from an earlier cybersecurity incident.
The company also indicated that its $14.5 billion acquisition of Penumbra is now expected to close in the first quarter of 2027, with extended regulatory reviews and higher financing costs affecting the transaction's economics. Boston Scientific
Primary source: Boston Scientific — Q3 2026 Financial Results, October 28
Why it matters strategically
This development is particularly relevant to international medical-device manufacturers operating in China.
China's volume-based procurement system changes the economics of market participation through centralized purchasing, tender competition, and lower prices.
The resulting pressure is not equivalent to a conventional import tariff.
A company may maintain regulatory approval and physical market access while experiencing a substantial deterioration in achievable selling prices.
This creates a different strategic problem from one involving tariffs or outright market exclusion.
The company must decide whether continued participation remains economically attractive.
